In 2023, the treatment success rate for patients with extensively drug-resistant tuberculosis (XDR TB) in the UK was 50%. The forecast for 2024 shows an increase to 52%, expected to grow steadily by 2 percentage points each year, reaching 60% by 2028. This represents a compound annual growth rate (CAGR) of approximately 3.7% over the five-year period. The consistent year-on-year increase suggests ongoing improvements in treatment methodologies and healthcare policies targeting XDR TB.
Future trends to watch for include advancements in medical treatments that could further enhance success rates, as well as potential challenges such as emerging drug resistance strains or healthcare resource limitations.
